Ascentage Pharma Group Internat (AAPG) Fair Value 2026

AAPG · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Ascentage Pharma Group Internat (AAPG) trades at $18.73. QOC: 5.7/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker
AAPG
Price
$18.73
Quality Score
5.7/10
Value Trap Risk
0/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give AAPG?

0 Intrinsic Value Models vs. Current Price ($18.73)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Ascentage Pharma Group Internat (AAPG) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Ascentage Pharma Group Internat currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About AAPG?

0 of 13 models are currently active for AAPG. See which stocks rank higher →

How Does AAPG Rank in Biotechnology?

Among 620 Biotechnology stocks, AAPG ranks #189 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Ascentage Pharma Group Internat operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating AAPG should weigh these sector-specific dynamics alongside our model-derived fair values.

Is AAPG a Value Trap?

CirclFi's Value Trap algorithm assigns AAPG a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Ascentage Pharma Group Internat. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Ascentage Pharma Group Internat's fundamental quality profile registers 5.7/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AAPG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Ascentage Pharma Group Internat Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

OTLCOncotelic Therapeutics, Inc.QOC 5.7FTREFortrea Holdings Inc.QOC 5.7ENTXEntera Bio Ltd.QOC 5.7CGONCG Oncology, Inc.QOC 5.7LITSLite Strategy, Inc.QOC 5.7IMAImageneBio, Inc.QOC 5.7AVXLAnavex Life Sciences Corp.QOC 4.9SANASana Biotechnology, Inc.QOC 4.2ARWRArrowhead Pharmaceuticals, Inc.QOC 7.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: OTLC · FTRE · ENTX · CGON · LITS · IMA · AVXL · SANA · ARWR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to AAPG?

7 companies across all industries closest to AAPG’s Quality of Company score of 5.7/10.

SINTSintx Technologies, Inc.QOC 5.7MFBIMonroe Federal Bancorp, Inc.QOC 5.7RCONRecon Technology, Ltd.QOC 5.7QURTQuarta-Rad, Inc.QOC 5.7TVGrupo Televisa, S.A.B.QOC 5.7VRNOVerano Holdings Corp.QOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SINT · MFBI · RCON · QURT · TV · VRNO · NVDA

Where Does AAPG Sit in CirclFi's Biotechnology Rankings?

AAPG is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Ascentage Pharma Group Internat’s Valuation?

What is Ascentage Pharma Group Internat's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Ascentage Pharma Group Internat (AAPG). The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AAPG overvalued or undervalued right now?

At $18.73, 0 of 0 active models suggest AAPG may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Ascentage Pharma Group Internat's business model in Biotechnology.

What does a Quality of Company score of 5.7 mean for AAPG?

Ascentage Pharma Group Internat's QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on AAPG?

CirclFi analyzes AAPG with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is AAPG a value trap in 2026?

Ascentage Pharma Group Internat's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Ascentage Pharma Group Internat (AAPG) a Quality of Company score of 5.7/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/AAPG/ · Methodology
Primary sources for this AAPG valuation
  • Financial statements: Ascentage Pharma Group Internat 10-K and 10-Q filings on SEC EDGAR (CIK 0002023311) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AAPG as of ; valuations recomputed .